ALLURION TECHNOLOGIES, INC. (ALUR)
ALLURION TECHNOLOGIES, INC. (ALUR)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 2,947 | 15,230 | NaN | NaN |
| Cost of revenue | 1,718 | 5,659 | NaN | NaN |
| Sales and marketing | 1,304 | 10,804 | NaN | NaN |
| Research and development-Clinical Trials And Medical Affairs | 343 | 3,020 | NaN | NaN |
| Research and development-Product Development | 205 | 1,848 | NaN | NaN |
| Research and development-Digital | 98 | 969 | NaN | NaN |
| Research and development-Quality And Regulatory | 266 | 1,733 | NaN | NaN |
| General and administrative | 2,744 | 21,353 | NaN | NaN |
| Interest paid on debt recorded at fair value | NaN | 379 | 481 | 1,550 |
| Provision for uncollectible accounts | NaN | 1,058 | 946 | 771 |
| Other segment items | -2,364 | 1,401 | NaN | NaN |
| Loss on extinguishment of debt | NaN | 0 | 0 | -660 |
| Net loss | -6,095 | -6,035 | -11,884 | -9,335 |
| Non-cash lease expense | 119 | 127 | 113 | 227 |
| Depreciation and amortization | 171 | 165 | 268 | 347 |
| Stock-based compensation | 638 | 702 | 531 | 1,016 |
| Other non-cash items, net | NaN | NaN | -269 | 851 |
| Unrealized exchange gain (loss) and other | NaN | 206 | NaN | NaN |
| Unrealized exchange (gain) loss | -90 | NaN | NaN | NaN |
| Change in fair value of revenue interest financing and pipe conversion option | NaN | -2,759 | -2,571 | 60 |
| Provision for inventory | 433 | 717 | 55 | 419 |
| Change in fair value of warrant liabilities | -4,324 | -3,586 | -1,481 | -2,064 |
| Change in fair value of earn-out liabilities | NaN | 62 | -18 | 105 |
| Warrant inducement expense | 4,145 | NaN | NaN | NaN |
| Change in fair value of debt | 750 | 1,165 | 1,250 | 4,530 |
| Change in fair value of revenue interest financing | -1,820 | NaN | NaN | NaN |
| Change in fair value of share obligation | -120 | -430 | -110 | 210 |
| Issuance costs associated with warrants recorded at fair value | 222 | 365 | 0 | 0 |
| Accounts receivable | -365 | 1,387 | -865 | -2,249 |
| Inventory | -176 | -278 | -53 | 839 |
| Prepaid expenses, other current and long-term assets | -172 | -316 | -327 | -10 |
| Lease liabilities | -73 | -184 | -76 | -337 |
| Accounts payable | -347 | 673 | -921 | -484 |
| Accrued expenses and other current liabilities | -1,363 | -1,958 | 1,143 | -2,762 |
| Net cash used in operating activities | -3,221 | -5,320 | -6,544 | -7,613 |
| Proceeds from private offerings, net of issuance costs | NaN | 4,597 | NaN | NaN |
| Proceeds from public offerings, net of issuance costs | NaN | 0 | -87 | 13,665 |
| Proceeds from equity line financing | NaN | 0 | 32 | 763 |
| Proceeds from warrant inducement, net of issuance costs | 2,866 | NaN | NaN | NaN |
| Net cash provided by financing activities | 2,866 | 4,597 | -55 | -71 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -355 | -723 | -6,599 | -7,684 |
| Cash and cash equivalents and restricted cash at beginning of period | 5,742 | 6,465 | 15,718 | NaN |
| Cash and cash equivalents and restricted cash at end of period | 5,387 | 5,742 | 6,465 | NaN |